Sign in
CompletedPhase 2

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Key facts

Who runs it
ModernaTX, Inc.
Where
Brookline, Cincinnati, Houston, Lafayette, Melrose Park, Meridian, Myrtle Beach, Norfolk, Philadelphia, Rockville, San Diego, Scottsdale, Southfield, Stockbridge, Tomball, and Wilmington, United StatesSee the 17 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
1,320 people enrolled
Started
7 Mar 2025
Ended
13 Oct 2025
Type of study
Interventional, 13 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • mRNA-1083 Composition 1 Dose A Lot A
  • mRNA-1083 Composition 1 Dose A Lot B
  • mRNA-1083 Composition 1 Dose B
  • mRNA-1083 Composition 1 Dose C
  • mRNA-1083 Composition 2 Dose A
  • mRNA-1083 Composition 2 Dose B
  • mRNA-1083 Composition 3 Dose A
  • mRNA-1083 Composition 3 Dose B
  • Influenza Vaccine
  • COVID-19 Vaccine
  • Investigational Influenza Vaccine
  • Investigational COVID-19 Vaccine Lot A
  • Investigational COVID-19 Vaccine Lot B
Record updated
20 October 2025

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Medically stable
  • Participants who could become pregnant: negative pregnancy test and contraception for at least 28 days prior to Day 1 and for at least 90 days after the study intervention administration
  • Have received ≥2 coronavirus disease 2019 (COVID-19) vaccines, with the last COVID-19 vaccine administered >150 days prior to Day 1

Who cannot take part

  • Tested positive for influenza by local health authority-approved testing methods within 150 days prior to Day 1
  • History of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 150 days prior to Day 1
  • Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (eg, infliximab), within 180 days prior to Day 1 or plans to do so during the study
  • Received or plans to receive any vaccine authorized or approved by a local health agency within 28 days prior to Day 1 or plans to do so within 28 days post study injection
  • Received a licensed seasonal influenza vaccine within 150 days prior to Day 1
  • Received a licensed/authorized COVID-19 vaccine within 150 days prior to Day 1
  • Received any investigational influenza vaccine, investigational COVID-19 vaccine, or investigational combination vaccine for influenza and COVID-19 within 12 months prior to Day 1
  • Participated in a clinical study with investigational treatment within 90 days prior to Day 1 (Baseline); Other protocol-defined inclusion/exclusion criteria may apply
  • History of a diagnosis or condition that is clinically unstable or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures

Where in United States

  • DM Clinical Research - BostonBrookline, United States
  • Velocity Clinical Research, Cincinnati, Mt. AuburnCincinnati, United States
  • Velocity Clinical Research, Cincinnati, SpringdaleCincinnati, United States
  • DM Clinical Research - BellaireHouston, United States
  • Velocity Clinical Research, LafayetteLafayette, United States
  • DM Clinical Research - ChicagoMelrose Park, United States
  • Velocity Clinical Research, BoiseMeridian, United States
  • Trial Management Associates, LLCMyrtle Beach, United States
  • Velocity Clinical Research - NorfolkNorfolk, United States
  • DM Clinical Research - PhiladelphiaPhiladelphia, United States
  • Velocity Clinical Research, RockvilleRockville, United States
  • Artemis Research (Headlands)San Diego, United States
  • Headlands Research - ScottsdaleScottsdale, United States
  • DM Clinical Research - DetroitSouthfield, United States
  • Clinical Research Atlanta - HeadlandsStockbridge, United States
  • DM Clinical Research, TomballTomball, United States
  • Trial Management Associates, LLCWilmington, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to <65 years of age.

The 13 groups in the trial

  • mRNA-1083 Composition 1 Dose A Lot ATreatment being tested

    Participants will receive single intramuscular (IM) injection of mRNA-1083 Composition 1 at Dose Level A Lot A on Day 1.

  • mRNA-1083 Composition 1 Dose A Lot BTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level A Lot B on Day 1.

  • mRNA-1083 Composition 1 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level B on Day 1.

  • mRNA-1083 Composition 1 Dose CTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level C on Day 1.

  • mRNA-1083 Composition 2 Dose ATreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level A on Day 1.

  • mRNA-1083 Composition 2 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level B on Day 1.

  • mRNA-1083 Composition 3 Dose ATreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 3 at Dose Level A on Day 1.

  • mRNA-1083 Composition 3 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 3 at Dose Level B on Day 1.

  • Influenza VaccineExisting treatment, for comparison

    Participants will receive single IM injection of Influenza Vaccine on Day 1.

  • COVID-19 VaccineExisting treatment, for comparison

    Participants will receive single IM injection of COVID-19 Vaccine on Day 1.

  • Investigational Influenza VaccineExisting treatment, for comparison

    Participants will receive single IM injection of Investigational Influenza Vaccine on Day 1.

  • Investigational COVID-19 Vaccine Lot AExisting treatment, for comparison

    Participants will receive single IM injection of Investigational COVID-19 Vaccine Lot A on Day 1.

  • Investigational COVID-19 Vaccine Lot BExisting treatment, for comparison

    Participants will receive single IM injection of Investigational COVID-19 Vaccine Lot B on Day 1.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Randomized, Observer-blind, Active-control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
Record updated
20 October 2025